ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual General Meeting

ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual General Meeting

 

  Both leading independent proxy advisors recommend shareholders vote for the re-election of incumbent directors, equity incentive plan amendment, and appointment of auditors  

 

  Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia's continued momentum  

 

  Company to release first quarter financial and operational results on May 4, 2023  

 

  Shareholders with questions or who require assistance voting their shares should contact Laurel Hill Advisory Group toll free within North America at 1-877-452-7184 (1-416-304-0211 outside North America), or by email at assistance@laurelhill.com   

 

 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company") today announced that leading independent proxy advisor Institutional Shareholder Services ("ISS") has recommended that Aurinia shareholders vote FOR the re-election of all eight incumbent directors to the Board of Directors (the "Board") at the Company's 2023 Annual General Meeting (the "Meeting").

 

ISS' positive recommendation follows an April 26 report from Glass Lewis, another leading independent proxy advisor, which also recommended that shareholders vote for the re-election of all incumbent directors.

 

Aurinia is pleased that ISS and Glass Lewis recognize the Board and management's pivotal role in the Company's continued growth and momentum. Aurinia's Board also appreciates the feedback and continued strong support of our shareholders.

 

  Aurinia's Board and management are taking the right steps to maximize shareholder value.  

 

Aurinia is well-positioned for significant value enhancement. The Company continues to build upon its robust sales growth – with net sales increasing over 194% in 2022 – and is making significant progress in expanding LUPKYNIS' availability in international markets in partnership with Otsuka.

 

In 2022, LUPKYNIS received approvals in the UK and EU and launched in several EU countries. Our efforts to gain regulatory approval in Japan remain on track, and we continue to expect a PMDA submission in the back half of 2023. We believe that our commercialization efforts will continue to unlock significant value for shareholders.

 

Each member of the Board has played an integral role in our progress to date. Our directors have the expertise needed to oversee and guide management and drive continued growth, including the commercialization of pharmaceutical and biotech products, business development, and international pharmaceutical operations. They also bring strong track records of value creation and commercial success.

 

  Aurinia's executive compensation aligns pay with performance.  

 

Aurinia disagrees with ISS' recommendation regarding the Company's advisory vote on executive compensation. Our Compensation Committee, which is comprised entirely of independent directors, makes all compensation decisions while leveraging advice from an independent third-party compensation consultant. The Compensation Committee conducts a rigorous and thorough review of market practices, especially those of peers, the general marketplace and other industry data points to determine performance targets, pay mix and levels that will best align management's interests with those of shareholders and support continued value creation. Aurinia has also engaged extensively with its shareholder base each year since the 2021 AGM and has made several improvements to the compensation program to incorporate feedback from shareholders, as detailed on page 54 of the proxy statement.

 

Importantly, ISS recognized that annual incentives for Aurinia executives were based largely on the achievement of pre-set corporate objectives, with the CEO's bonus being based solely on such goals. Aurinia has also previously announced that it will add a performance component to Long-Term Incentive Plan awards in 2023.

 

The Company also notes that leading proxy advisor Glass Lewis recommended shareholders vote "FOR" Aurinia's say-on-pay resolution, along with all other proposals. We will continue to listen to shareholder feedback regarding our executive compensation and other important matters.

 

  AURINIA SHAREHOLDERS: PROTECT THE VALUE OF YOUR INVESTMENT BY VOTING ONLINE, BY MAIL, OR TELEPHONE TODAY.  

 

To ensure Aurinia's continued momentum at a pivotal time for the Company, the Board encourages all shareholders to vote "FOR" ALL proposals today.

 

The virtual-only meeting will be held via live audio webcast online using the LUMI meeting platform at https://web.lumiagm.com/467056294 (password (case sensitive): aurinia2023) on Wednesday, May 17, 2023 at 12:00 pm, Eastern Time.

 

  Company to Report First Quarter 2023 Financial and Operational Results on May 4, 2023  

 

As previously announced , Aurinia will release financial and operational results for the first quarter of 2023, on Thursday, May 4, 2023, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (888) 645-4404 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com . A replay of the webcast will be available on Aurinia's website.

 

  Questions or Require Voting Assistance?  

 

Contact our proxy solicitation agent, Laurel Hill Advisory Group toll free within North America at 1-877-452-7184 (1-416-304-0211 outside North America), or by email at assistance@laurelhill.com .

 

  About LUPKYNIS  

 

LUPKYNIS ® is the first U.S. FDA- and EC-approved oral medicine for the treatment of adult patients with active LN. LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. Dose modifications can be made based on Aurinia's proprietary personalized eGFR-based dosing protocol. Boxed Warning, warnings, and precautions for LUPKYNIS are consistent with those of other CNI-immunosuppressive treatments.

 

  About Aurinia  

 

 Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company's head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

 

  

  

  Investor/Media Contact:  
Aurinia@westwicke.com  

 

News Provided by Business Wire via QuoteMedia

AUPH
The Conversation (0)
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

 

 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission (SEC).

 

Under U.S. federal securities laws, equity awards issued as employee compensation must be registered under the Securities Act of 1933, as amended, via an S-8 registration statement or qualify for an exemption from registration. This Form S-8 registers previously issued and disclosed stock options and restricted stock units (RSUs) that were granted as inducement awards to employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Announces 2023 Annual General Meeting Results

Aurinia Announces 2023 Annual General Meeting Results

 

 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company") today announced voting results for its annual general meeting (the "Meeting") of shareholders held on May 17, 2023.

 

Shareholders re-elected six of eight incumbent directors to the Board of Directors (the "Board"). Two directors, George Milne and Joseph ("Jay") Hagan, while elected under applicable corporate law, received less than majority support and have submitted their resignations for consideration by the Board, pursuant to the Company's Majority Voting Policy. In accordance with the policy, the Board intends to act expeditiously in respect to the submitted resignations to ensure an orderly transition.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS®  AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

 

  First study to assess histologic changes in the kidneys of patients with lupus nephritis treated with LUPKYNIS ® (voclosporin)  

 

  Treatment was not associated with chronic injury, with the average chronicity index remaining stable in both treatment arms from baseline to follow-up  

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

 

  $34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year  

 

  Increases 2023 revenue guidance range to $135 - $155 million from net product sales of LUPKYNIS  

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS®  For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® For Adults with Active Lupus Nephritis

 

 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS ® (voclosporin) as an option for treating adults with active lupus nephritis (LN) class III, IV or V (including mixed class III/V and IV/V) 1 , when provided in combination with mycophenolate mofetil (MMF).

 

The NICE recommendation applies to England and Wales and follows the recent Medicines and Healthcare Products Regulatory Agency (MHRA) authorization of voclosporin licensed in Great Britain for the treatment of active LN in adult patients.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less
Amplia Therapeutics

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.
Keep reading...Show less

Latest Press Releases

Related News

×